{"analyses":[{"ciLowerLimit":"0.7","ciPctValue":"95","ciUpperLimit":"3.7","estimateComment":"For all analyses, MMF arm in numerator, and placebo arm in denominator. Hazard ratio estimate includes 3 efficacy success events that occurred after two years in the placebo arm.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":".22","pValueComment":"P values are 2 sided and are based on likelihood ratio statistics.","paramType":"Hazard Ratio (HR)","paramValue":"1.66","statisticalComment":"Analysis for all endpoints was stratified by number of affected organs and type of conditioning regimen.","statisticalMethod":"Regression, Cox","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"77"}],"units":"Participants"}],"description":"Withdrawal of all systemic immunosuppressive treatment after resolution of chronic GVHD, before death or onset of recurrent malignancy","groups":[{"description":"Patients receive oral mycophenolate mofetil 1000 mg twice daily.","id":"OG000","title":"Mycophenolate Mofetil"},{"description":"Patients receive oral placebo twice daily","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Cure of Chronic GVHD Without Resorting to Secondary Systemic Therapy","type":"PRIMARY","unitOfMeasure":"participants"}